🚨5 Stocks to Buy Entering 2026 (Part I)🧐👇 Please find below a list...
Michael. Z@MichaelZero10
19 views
Jan 19, 2026
~6 min read
Advertisement
1
🚨5 Stocks to Buy Entering 2026 (Part I)🧐👇
Please find below a list of Stocks that you could use to Generate Great Returns in 2026.
1. $ENPH 🇺🇸 | Enphase (Mkt Cap: $4.5bn)
Rationale:🔎
• $ENPH has a strong recovery potential considering interest rates are dropping in the U.S.
• Indeed the current federal funds rate is 3.64%, with a Target Range set by the FED of 3.50-3.75%.
• Inflation seems to be currently under control, therefore the FED could continue to lower interest rates.
• This trend would significantly improve financing conditions for Solar Energy projects in the U.S.
• Better financing conditions should bring additional demand and support the business.
• Investors have already priced-in the Worst case scenario, consequently they could be positively surprised over the next few quarters.
• Indeed investors are expecting only ~$254m of revenue in Q1 2026E, which is significantly low compared to revenue generated in Q1 2025 or Q1 2024.
• $ENPH is set to launch several new technologies in 2026, including the IQ Bidirectional EV Charger, which will be available in H2 2026.
Risks:⚡️
• Macroeconomic conditions could be less supportive than expected with a surge of inflation that could force the FED to tighten the monetary policy by increasing the interest rates in the U.S.
• Under this new Macroeconomic scenario, Solar Energy projects could be significantly affected in the U.S.
• The New technologies expected in H2 2026 could bring less business than anticipated.
Valuation and Key Metrics:🧐
- 2026E EV/Sales= 3.42x;
- 2026E Sales Growth = (16.05)%;
- 2026E EBITDA Margin = 24.96%;
Please find below a list of Stocks that you could use to Generate Great Returns in 2026.
1. $ENPH 🇺🇸 | Enphase (Mkt Cap: $4.5bn)
Rationale:🔎
• $ENPH has a strong recovery potential considering interest rates are dropping in the U.S.
• Indeed the current federal funds rate is 3.64%, with a Target Range set by the FED of 3.50-3.75%.
• Inflation seems to be currently under control, therefore the FED could continue to lower interest rates.
• This trend would significantly improve financing conditions for Solar Energy projects in the U.S.
• Better financing conditions should bring additional demand and support the business.
• Investors have already priced-in the Worst case scenario, consequently they could be positively surprised over the next few quarters.
• Indeed investors are expecting only ~$254m of revenue in Q1 2026E, which is significantly low compared to revenue generated in Q1 2025 or Q1 2024.
• $ENPH is set to launch several new technologies in 2026, including the IQ Bidirectional EV Charger, which will be available in H2 2026.
Risks:⚡️
• Macroeconomic conditions could be less supportive than expected with a surge of inflation that could force the FED to tighten the monetary policy by increasing the interest rates in the U.S.
• Under this new Macroeconomic scenario, Solar Energy projects could be significantly affected in the U.S.
• The New technologies expected in H2 2026 could bring less business than anticipated.
Valuation and Key Metrics:🧐
- 2026E EV/Sales= 3.42x;
- 2026E Sales Growth = (16.05)%;
- 2026E EBITDA Margin = 24.96%;
2
2. $UNH 🇺🇸 | UnitedHealth ($316bn)
Rationale:🔎
• $UNH Stock could be a great defensive play for the portfolio if Equity Markets start to correct significantly.
• The Business has not fully-recovered following difficult recent quarters.
• Indeed, $UNH generated ~$35bn of EBITDA in 2023 and investors are expecting only ~$28bn in 2026, which highlights the potential recovery achievable over the next few quarters.
• Investors Buying $UNH Stock get the opportunity to benefit from a recovery and at the same time collect some dividends (~2.6% dividend yield), which is not too bad if Equity Markets go down in 2026.
• $UNH is a recession proof Stock and would continue to perform well under turbulent Equity Markets.
Risks:⚡️
• Macroeconomic conditions could stay stronger than anticipated and investors could be less attracted by defensive stocks.
• Under this scenario $UNH could underperform.
• The full-recovery could take longer than anticipated.
Valuation and Key Metrics:🧐
- 2026E EV/EBITDA= 13.18x;
- 2026E EBITDA Growth = 8%;
- 2026E EBITDA Margin = 6.19%;
Rationale:🔎
• $UNH Stock could be a great defensive play for the portfolio if Equity Markets start to correct significantly.
• The Business has not fully-recovered following difficult recent quarters.
• Indeed, $UNH generated ~$35bn of EBITDA in 2023 and investors are expecting only ~$28bn in 2026, which highlights the potential recovery achievable over the next few quarters.
• Investors Buying $UNH Stock get the opportunity to benefit from a recovery and at the same time collect some dividends (~2.6% dividend yield), which is not too bad if Equity Markets go down in 2026.
• $UNH is a recession proof Stock and would continue to perform well under turbulent Equity Markets.
Risks:⚡️
• Macroeconomic conditions could stay stronger than anticipated and investors could be less attracted by defensive stocks.
• Under this scenario $UNH could underperform.
• The full-recovery could take longer than anticipated.
Valuation and Key Metrics:🧐
- 2026E EV/EBITDA= 13.18x;
- 2026E EBITDA Growth = 8%;
- 2026E EBITDA Margin = 6.19%;
3
3. $DLO 🇺🇾 | DLocal ($4.3bn)
Rationale:🔎
• The Business is well run and managed by Pedro Arnt, who is a best-in-class CEO.
• The Business still has plenty of room to improve margins and generate more Free Cash Flows.
• In 2022 $DLO generated ~32.35% EBITDA Margin while investors are expected ~26.35% in 2026.
• Indeed, these historical data points are supporting strong margin improvement potential.
• As the FED is currently reducing interest rates in the U.S, investors would be less attracted by U.S. Government Bonds and that should make the U.S Dollar weaker against major and emergent currencies.
• Historically a weaker U.S. Dollar supports Stocks in Emerging Markets such as $DLO.
• Valuation looks really attractive considering $DLO is trading at only 10x EV/ 2026 EBITDA for ~31% EBITDA growth expected in 2026.
• Usually Stocks with similar profile trade at 15-16x EV/EBITDA, which means there is +50% upside potential only by considering a simple rerating.
Risks:⚡️
• Poor execution could still happen even if the Business has a strong Management Team.
• Macroeconomic conditions could change rapidly and interest rates in the U.S. could rise.
• Under this scenario Stocks in Emerging Markets could be severely affected, as investors prefer to allocate their capital in mature markets when the economic environment deteriorates.
Valuation and Key Metrics:🧐
- 2026E EV/EBITDA= 10.19x;
- 2026E EBITDA Growth = 31%;
- 2026E EBITDA Margin = 26.35%;
Rationale:🔎
• The Business is well run and managed by Pedro Arnt, who is a best-in-class CEO.
• The Business still has plenty of room to improve margins and generate more Free Cash Flows.
• In 2022 $DLO generated ~32.35% EBITDA Margin while investors are expected ~26.35% in 2026.
• Indeed, these historical data points are supporting strong margin improvement potential.
• As the FED is currently reducing interest rates in the U.S, investors would be less attracted by U.S. Government Bonds and that should make the U.S Dollar weaker against major and emergent currencies.
• Historically a weaker U.S. Dollar supports Stocks in Emerging Markets such as $DLO.
• Valuation looks really attractive considering $DLO is trading at only 10x EV/ 2026 EBITDA for ~31% EBITDA growth expected in 2026.
• Usually Stocks with similar profile trade at 15-16x EV/EBITDA, which means there is +50% upside potential only by considering a simple rerating.
Risks:⚡️
• Poor execution could still happen even if the Business has a strong Management Team.
• Macroeconomic conditions could change rapidly and interest rates in the U.S. could rise.
• Under this scenario Stocks in Emerging Markets could be severely affected, as investors prefer to allocate their capital in mature markets when the economic environment deteriorates.
Valuation and Key Metrics:🧐
- 2026E EV/EBITDA= 10.19x;
- 2026E EBITDA Growth = 31%;
- 2026E EBITDA Margin = 26.35%;
4
4. $UAMY 🇺🇸 | United States Antimony ($1bn)
Rationale:🔎
• $UAMY is the only U.S. producer of antimony products materials that are critical to making batteries, solar panels, and ordnance for the military.
• While China dominates the global antimony market, it began restricting U.S. exports last year.
• The standoff helped $UAMY secure a 5y, $245M deal with the U.S Government in September and a $107M commercial contract that the company disclosed in November.
• Valuation looks really attractive at 7.61x EV/ 2026 Sales considering revenue growth expectations at ~202%.
• Indeed $UAMY expects $40-43M in revenue for 2025, and $125M in 2026.
Risks:⚡️
• Revenue growth could slow-down or be delayed due to poor execution from the management team.
• $UAMY is highly sensitive to growth expectations.
• Consequently, any miss in terms of revenue could bring the stock down massively.
Valuation and Key Metrics:🧐
- 2026E EV/Sales= 7.61x;
- 2026E Sales Growth = 202%;
- 2026E EBITDA Margin = 23.32%;
Rationale:🔎
• $UAMY is the only U.S. producer of antimony products materials that are critical to making batteries, solar panels, and ordnance for the military.
• While China dominates the global antimony market, it began restricting U.S. exports last year.
• The standoff helped $UAMY secure a 5y, $245M deal with the U.S Government in September and a $107M commercial contract that the company disclosed in November.
• Valuation looks really attractive at 7.61x EV/ 2026 Sales considering revenue growth expectations at ~202%.
• Indeed $UAMY expects $40-43M in revenue for 2025, and $125M in 2026.
Risks:⚡️
• Revenue growth could slow-down or be delayed due to poor execution from the management team.
• $UAMY is highly sensitive to growth expectations.
• Consequently, any miss in terms of revenue could bring the stock down massively.
Valuation and Key Metrics:🧐
- 2026E EV/Sales= 7.61x;
- 2026E Sales Growth = 202%;
- 2026E EBITDA Margin = 23.32%;
5
5. $CORT 🇺🇸 | Corcept Therapeutics ($3.7bn)
Rationale:🔎
• $CORT's main drug, Korlym, treats Cushing’s syndrome, a rare hormonal disorder caused by too much exposure to cortisol.
• Sales are strong, but the company aims to leverage its expertise in cortisol to expand into other areas, as its early research shows controlling cortisol can help treat diseases ranging from cancer to Amyotrophic Lateral Sclerosis.
• The company reported positive Phase III trial results for its new ovarian cancer treatment.
• $CORT Stock dropped by 55% over the last few days following the FDA rejection of Corcept’s drug relacorilant, which was expected to treat hypertension.
• Recent volatility could present a great opportunity to Buy the stock at discount.
• Valuation looks really attractive considering $CORT is trading at only 10x EV/ 2026 EBITDA for ~113% EBITDA growth expected in 2026.
Risks:⚡️
• Near-term uncertainty and disappointment often translate into selling pressure in biotech stocks, particularly when a pivotal drug misses approval.
• $CORT still has revenue from Korlym and other pipeline programs but relacorilant’s delay could affect further the future growth narrative.
Valuation and Key Metrics:🧐
- 2026E EV/EBITDA= 10.23x;
- 2026E EBITDA Growth = 113%;
- 2026E EBITDA Margin = 29.45%;
Rationale:🔎
• $CORT's main drug, Korlym, treats Cushing’s syndrome, a rare hormonal disorder caused by too much exposure to cortisol.
• Sales are strong, but the company aims to leverage its expertise in cortisol to expand into other areas, as its early research shows controlling cortisol can help treat diseases ranging from cancer to Amyotrophic Lateral Sclerosis.
• The company reported positive Phase III trial results for its new ovarian cancer treatment.
• $CORT Stock dropped by 55% over the last few days following the FDA rejection of Corcept’s drug relacorilant, which was expected to treat hypertension.
• Recent volatility could present a great opportunity to Buy the stock at discount.
• Valuation looks really attractive considering $CORT is trading at only 10x EV/ 2026 EBITDA for ~113% EBITDA growth expected in 2026.
Risks:⚡️
• Near-term uncertainty and disappointment often translate into selling pressure in biotech stocks, particularly when a pivotal drug misses approval.
• $CORT still has revenue from Korlym and other pipeline programs but relacorilant’s delay could affect further the future growth narrative.
Valuation and Key Metrics:🧐
- 2026E EV/EBITDA= 10.23x;
- 2026E EBITDA Growth = 113%;
- 2026E EBITDA Margin = 29.45%;
6
Final Thoughts
• These are 5 stocks in different sectors (Solar Energy, Healthcare, Financials, Mining, and Pharmaceutical) that could perform well in 2026 depending on macroeconomic conditions.
• I will write another thread with 5 more ideas (Part II) over the next few days.
• Please note that I personally own $ENPH, $UNH, and $DLO. $UAMY and $CORT are stocks that I found interesting and follow closely.
• Which Stock will perform the best ? 🤔
• These are 5 stocks in different sectors (Solar Energy, Healthcare, Financials, Mining, and Pharmaceutical) that could perform well in 2026 depending on macroeconomic conditions.
• I will write another thread with 5 more ideas (Part II) over the next few days.
• Please note that I personally own $ENPH, $UNH, and $DLO. $UAMY and $CORT are stocks that I found interesting and follow closely.
• Which Stock will perform the best ? 🤔
